{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:33:38Z","timestamp":1791516818578,"version":"4.3.4"},"reference-count":139,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s12325-025-03387-1","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T08:25:17Z","timestamp":1764923117000},"page":"468-519","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Selection of Endothelin Receptor Antagonists in the Treatment of Pulmonary Arterial Hypertension: A Comprehensive Narrative Review"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-3388-0616","authenticated-orcid":false,"given":"Naomi G.","family":"Habib","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0991-7045","authenticated-orcid":false,"given":"Ankita","family":"Adhia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2310-3793","authenticated-orcid":false,"given":"David","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4147-6242","authenticated-orcid":false,"given":"Marinella","family":"Sandros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8847-4767","authenticated-orcid":false,"given":"Paul","family":"Guichard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"key":"3387_CR1","doi-asserted-by":"publisher","first-page":"2102334","DOI":"10.1183\/13993003.02334-2021","volume":"59","author":"R Naeije","year":"2022","unstructured":"Naeije R, Richter MJ, Rubin LJ. The physiological basis of pulmonary arterial hypertension. Eur Respir J. 2022;59:2102334.","journal-title":"Eur Respir J"},{"key":"3387_CR2","doi-asserted-by":"publisher","DOI":"10.1002\/pul2.12020","volume":"12","author":"S Emmons-Bell","year":"2022","unstructured":"Emmons-Bell S, Johnson C, Boon-Dooley A, et al. Prevalence, incidence, and survival of pulmonary arterial hypertension: a systematic review for the global burden of disease 2020 study. Pulm Circ. 2022;12:e12020.","journal-title":"Pulm Circ"},{"key":"3387_CR3","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","volume":"43","author":"M Humbert","year":"2022","unstructured":"Humbert M, Kovacs G, Hoeper MM, ESC\/ERS Scientific Document Group, et al. 2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43:3618\u201331 (Erratum in: Eur Heart J. 2023;44:1312).","journal-title":"Eur Heart J"},{"key":"3387_CR4","doi-asserted-by":"publisher","first-page":"2401325","DOI":"10.1183\/13993003.01325-2024","volume":"64","author":"KM Chin","year":"2024","unstructured":"Chin KM, Gaine SP, Gerges C, et al. Treatment algorithm for pulmonary arterial hypertension. Eur Respir J. 2024;64:2401325.","journal-title":"Eur Respir J"},{"key":"3387_CR5","unstructured":"Tracleer\u00ae (bosentan) tablets. Prescribing information. February 2024. https:\/\/www.tracleer.com\/assets\/PDFs\/Tracleer_Full_Prescribing_Information.pdf. Accessed 23 Apr 2025."},{"key":"3387_CR6","unstructured":"Letairis\u00ae (ambrisentan) tablets. Prescribing information. Revised April 2025. https:\/\/www.gilead.com\/~\/media\/Files\/pdfs\/medicines\/cardiovascular\/letairis\/letairis_pi.pdf. Accessed 23 Apr 2025."},{"key":"3387_CR7","unstructured":"Opsumit\u00ae (macitentan) tablets. Prescribing information. April 2025. https:\/\/www.opsumit.com\/opsumit-prescribing-information.pdf. Accessed 23 Apr 2025."},{"key":"3387_CR8","unstructured":"Opsynvi\u00ae (macitentan and tadalafil) tablets. Prescribing information. April 2025. https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/OPSYNVI-pi.pdf Accessed 23 Apr 2025."},{"key":"3387_CR9","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1124\/pr.115.011833","volume":"68","author":"AP Davenport","year":"2016","unstructured":"Davenport AP, Hyndman KA, Dhaun N, et al. Endothelin. Pharmacol Rev. 2016;68:357\u2013418.","journal-title":"Pharmacol Rev"},{"key":"3387_CR10","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1161\/01.CIR.102.19.2434","volume":"102","author":"TF L\u00fcscher","year":"2000","unstructured":"L\u00fcscher TF, Barton M. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation. 2000;102:2434\u201340.","journal-title":"Circulation"},{"key":"3387_CR11","first-page":"62","volume":"2014","author":"AH Chester","year":"2014","unstructured":"Chester AH, Yacoub MH. The role of endothelin-1 in pulmonary arterial hypertension. Glob Cardiol Sci Pract. 2014;2014:62\u201378.","journal-title":"Glob Cardiol Sci Pract"},{"key":"3387_CR12","doi-asserted-by":"publisher","first-page":"175346661882344","DOI":"10.1177\/1753466618823440","volume":"13","author":"C Belge","year":"2019","unstructured":"Belge C, Delcroix M. Treatment of pulmonary arterial hypertension with the dual endothelin receptor antagonist macitentan: clinical evidence and experience. Ther Adv Respir Dis. 2019;13:1753466618823440.","journal-title":"Ther Adv Respir Dis"},{"key":"3387_CR13","doi-asserted-by":"publisher","first-page":"R721","DOI":"10.1152\/ajpregu.00475.2015","volume":"311","author":"M Clozel","year":"2016","unstructured":"Clozel M. Endothelin research and the discovery of macitentan for the treatment of pulmonary arterial hypertension. Am J Physiol Regul Integr Comp Physiol. 2016;311:R721\u20136.","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"7","key":"3387_CR14","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.rmed.2009.02.016","volume":"103","author":"TK Trow","year":"2009","unstructured":"Trow TK, Taichman DB. Endothelin receptor blockade in the management of pulmonary arterial hypertension: selective and dual antagonism. Respir Med. 2009;103(7):951\u201362 (Erratum in: Respir Med. 2013;107:1463).","journal-title":"Respir Med"},{"key":"3387_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0047662","volume":"7","author":"J Gatfield","year":"2012","unstructured":"Gatfield J, Mueller Grandjean C, Sasse T, Clozel M, Nayler O. Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells. PLoS ONE. 2012;7:e47662.","journal-title":"PLoS ONE"},{"key":"3387_CR16","doi-asserted-by":"publisher","first-page":"7849","DOI":"10.1021\/jm3009103","volume":"55","author":"MH Bolli","year":"2012","unstructured":"Bolli MH, Boss C, Binkert C, et al. The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N\u2019-propylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist. J Med Chem. 2012;55:7849\u201361.","journal-title":"J Med Chem"},{"key":"3387_CR17","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41421-024-00705-9","volume":"10","author":"J Hou","year":"2024","unstructured":"Hou J, Liu S, Zhang X, et al. Structural basis of antagonist selectivity in endothelin receptors. Cell Discov. 2024;10:79.","journal-title":"Cell Discov"},{"key":"3387_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0107809","volume":"9","author":"J Gatfield","year":"2014","unstructured":"Gatfield J, Mueller Grandjean C, Bur D, Bolli MH, Nayler O. Distinct ETA receptor binding mode of macitentan as determined by site directed mutagenesis. PLoS ONE. 2014;9:e107809.","journal-title":"PLoS ONE"},{"key":"3387_CR19","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1038\/nsmb.3450","volume":"24","author":"W Shihoya","year":"2017","unstructured":"Shihoya W, Nishizawa T, Yamashita K, et al. X-ray structures of endothelin ETB receptor bound to clinical antagonist bosentan and its analog. Nat Struct Mol Biol. 2017;24:758\u201364.","journal-title":"Nat Struct Mol Biol"},{"key":"3387_CR20","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1124\/jpet.108.142976","volume":"327","author":"M Iglarz","year":"2008","unstructured":"Iglarz M, Binkert C, Morrison K, et al. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther. 2008;327:736\u201345.","journal-title":"J Pharmacol Exp Ther"},{"key":"3387_CR21","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1183\/09031936.00078207","volume":"31","author":"J Dupuis","year":"2008","unstructured":"Dupuis J, Hoeper MM. Endothelin receptor antagonists in pulmonary arterial hypertension. Eur Respir J. 2008;31:407\u201315.","journal-title":"Eur Respir J"},{"key":"3387_CR22","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.lfs.2014.02.018","volume":"118","author":"M Iglarz","year":"2014","unstructured":"Iglarz M, Bossu A, Wanner D, et al. Comparison of pharmacological activity of macitentan and bosentan in preclinical models of systemic and pulmonary hypertension. Life Sci. 2014;118:333\u20139.","journal-title":"Life Sci"},{"key":"3387_CR23","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s40256-014-0095-y","volume":"15","author":"MC Chaumais","year":"2015","unstructured":"Chaumais MC, Guignabert C, Savale L, et al. Clinical pharmacology of endothelin receptor antagonists used in the treatment of pulmonary arterial hypertension. Am J Cardiovasc Drugs. 2015;15:13\u201326.","journal-title":"Am J Cardiovasc Drugs"},{"key":"3387_CR24","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s40262-015-0255-5","volume":"54","author":"PN Sidharta","year":"2015","unstructured":"Sidharta PN, Treiber A, Dingemanse J. Clinical pharmacokinetics and pharmacodynamics of the endothelin receptor antagonist macitentan. Clin Pharmacokinet. 2015;54:457\u201371.","journal-title":"Clin Pharmacokinet"},{"key":"3387_CR25","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.2165\/00003088-200443150-00003","volume":"43","author":"J Dingemanse","year":"2004","unstructured":"Dingemanse J, van Giersbergen PL. Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. Clin Pharmacokinet. 2004;43:1089\u2013115.","journal-title":"Clin Pharmacokinet"},{"key":"3387_CR26","first-page":"1675","volume":"10","author":"TJ Monaco","year":"2016","unstructured":"Monaco TJ, Davila CD. Safety, efficacy, and clinical utility of macitentan in the treatment of pulmonary arterial hypertension. Drug Des Devel Ther. 2016;10:1675\u201382.","journal-title":"Drug Des Devel Ther"},{"key":"3387_CR27","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1046\/j.1365-2125.2002.01608.x","volume":"53","author":"PL van Giersbergen","year":"2002","unstructured":"van Giersbergen PL, Halabi A, Dingemanse J. Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole. Br J Clin Pharmacol. 2002;53:589\u201395.","journal-title":"Br J Clin Pharmacol"},{"key":"3387_CR28","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1002\/jcph.152","volume":"53","author":"PN Sidharta","year":"2013","unstructured":"Sidharta PN, van Giersbergen PL, Dingemanse J. Safety, tolerability, pharmacokinetics, and pharmacodynamics of macitentan, an endothelin receptor antagonist, in an ascending multiple-dose study in healthy subjects. J Clin Pharmacol. 2013;53:1131\u20138.","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"3387_CR29","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1517\/14740338.2014.859674","volume":"13","author":"J Dingemanse","year":"2014","unstructured":"Dingemanse J, Sidharta PN, Maddrey WC, Rubin LJ, Mickail H. Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension. Expert Opin Drug Saf. 2014;13(3):391\u2013405.","journal-title":"Expert Opin Drug Saf"},{"issue":"3","key":"3387_CR30","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/jcph.193","volume":"54","author":"PN Sidharta","year":"2014","unstructured":"Sidharta PN, Lindegger N, Ul\u010d I, Dingemanse J. Pharmacokinetics of the novel dual endothelin receptor antagonist macitentan in subjects with hepatic or renal impairment. J Clin Pharmacol. 2014;54(3):291\u2013300.","journal-title":"J Clin Pharmacol"},{"key":"3387_CR31","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/clpt.2010.120","volume":"88","author":"R Spence","year":"2010","unstructured":"Spence R, Mandagere A, Richards DB, Magee MH, Dufton C, Boinpally R. Potential for pharmacokinetic interactions between ambrisentan and cyclosporine. Clin Pharmacol Ther. 2010;88:513\u201320.","journal-title":"Clin Pharmacol Ther"},{"key":"3387_CR32","doi-asserted-by":"publisher","first-page":"875","DOI":"10.2165\/11539110-000000000-00000","volume":"30","author":"B Harrison","year":"2010","unstructured":"Harrison B, Magee MH, Mandagere A, et al. Effects of rifampicin (rifampin) on the pharmacokinetics and safety of ambrisentan in healthy subjects: a single-sequence, open-label study. Clin Drug Investig. 2010;30:875\u201385.","journal-title":"Clin Drug Investig"},{"key":"3387_CR33","doi-asserted-by":"publisher","first-page":"4962","DOI":"10.1002\/jps.21789","volume":"98","author":"R Spence","year":"2009","unstructured":"Spence R, Mandagere A, Harrison B, Dufton C, Boinpally R. No clinically relevant pharmacokinetic and safety interactions of ambrisentan in combination with tadalafil in healthy volunteers. J Pharm Sci. 2009;98:4962\u201374.","journal-title":"J Pharm Sci"},{"key":"3387_CR34","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1177\/0091270008324180","volume":"48","author":"R Spence","year":"2008","unstructured":"Spence R, Mandagere A, Dufton C, Venitz J. Pharmacokinetics and safety of ambrisentan in combination with sildenafil in healthy volunteers. J Clin Pharmacol. 2008;48:1451\u20139.","journal-title":"J Clin Pharmacol"},{"key":"3387_CR35","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/S0140-6736(01)06250-X","volume":"358","author":"RN Channick","year":"2001","unstructured":"Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet. 2001;358:1119\u201323.","journal-title":"Lancet"},{"key":"3387_CR36","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa012212","volume":"346","author":"LJ Rubin","year":"2002","unstructured":"Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346:896\u2013903 (Erratum in: N Engl J Med 2002;346:1258).","journal-title":"N Engl J Med"},{"key":"3387_CR37","doi-asserted-by":"publisher","first-page":"3010","DOI":"10.1161\/CIRCULATIONAHA.107.742510","volume":"117","author":"N Gali\u00e8","year":"2008","unstructured":"Gali\u00e8 N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008;117:3010\u20139.","journal-title":"Circulation"},{"key":"3387_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(16)00027-8","volume":"4","author":"AC Lajoie","year":"2016","unstructured":"Lajoie AC, Lauzi\u00e8re G, Lega JC, et al. Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis. Lancet Respir Med. 2016;4:291305.","journal-title":"Lancet Respir Med"},{"issue":"6 Suppl","key":"3387_CR39","first-page":"S115","volume":"20","author":"SM Studer","year":"2014","unstructured":"Studer SM, Gilkin RJ Jr. Clinical trial designs in PAH: shifting from functional measurements to long-term clinical outcomes. Am J Manag Care. 2014;20(6 Suppl):S115\u201322.","journal-title":"Am J Manag Care"},{"key":"3387_CR40","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1213917","volume":"369","author":"T Pulido","year":"2013","unstructured":"Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369:809\u201318.","journal-title":"N Engl J Med"},{"key":"3387_CR41","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1056\/NEJMoa1413687","volume":"373","author":"N Gali\u00e8","year":"2015","unstructured":"Gali\u00e8 N, Barber\u00e0 JA, Frost AE, et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med. 2015;373:834\u201344.","journal-title":"N Engl J Med"},{"key":"3387_CR42","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1183\/13993003.02044-2014","volume":"46","author":"V McLaughlin","year":"2015","unstructured":"McLaughlin V, Channick RN, Ghofrani HA, et al. Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension. Eur Respir J. 2015;46:405\u201313.","journal-title":"Eur Respir J"},{"key":"3387_CR43","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1186\/s12890-020-01241-4","volume":"20","author":"M Schlueter","year":"2020","unstructured":"Schlueter M, Beaudet A, Davies E, Gurung B, Karabis A. Evidence synthesis in pulmonary arterial hypertension: a systematic review and critical appraisal. BMC Pulm Med. 2020;20:202.","journal-title":"BMC Pulm Med"},{"key":"3387_CR44","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/jcpt.13481","volume":"47","author":"Q Zhao","year":"2022","unstructured":"Zhao Q, Guo N, Chen J, Parks D, Tian Z. Comparative assessment of efficacy and safety of ambrisentan and bosentan in patients with pulmonary arterial hypertension: a meta-analysis. J Clin Pharm Ther. 2022;47:146\u201356.","journal-title":"J Clin Pharm Ther"},{"key":"3387_CR45","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1080\/10717544.2021.1927243","volume":"28","author":"W Fu","year":"2021","unstructured":"Fu W, He W, Li Y, et al. Efficacy and safety of novel-targeted drugs in the treatment of pulmonary arterial hypertension: a Bayesian network meta-analysis. Drug Deliv. 2021;28:1007\u201319.","journal-title":"Drug Deliv"},{"key":"3387_CR46","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1183\/09031936.04.00028404","volume":"24","author":"M Humbert","year":"2004","unstructured":"Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J. 2004;24:353\u20139.","journal-title":"Eur Respir J"},{"key":"3387_CR47","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1016\/S0140-6736(08)60919-8","volume":"371","author":"N Gali\u00e8","year":"2008","unstructured":"Gali\u00e8 N, Rubin LJ, Hoeper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet. 2008;371:2093\u2013100.","journal-title":"Lancet"},{"key":"3387_CR48","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.ijcard.2013.12.179","volume":"172","author":"G Simonneau","year":"2014","unstructured":"Simonneau G, Gali\u00e8 N, Jansa P, et al. Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients. Int J Cardiol. 2014;172:332\u20139.","journal-title":"Int J Cardiol"},{"issue":"6","key":"3387_CR49","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1111\/crj.12774","volume":"12","author":"X Chen","year":"2018","unstructured":"Chen X, Zhai Z, Huang K, Xie W, Wan J, Wang C. Bosentan therapy for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: a systemic review and meta-analysis. Clin Respir J. 2018;12(6):2065\u201374.","journal-title":"Clin Respir J"},{"key":"3387_CR50","doi-asserted-by":"publisher","first-page":"701","DOI":"10.3904\/kjim.2013.28.6.701","volume":"28","author":"YH Lee","year":"2013","unstructured":"Lee YH, Song GG. Meta-analysis of randomized controlled trials of bosentan for treatment of pulmonary arterial hypertension. Korean J Intern Med. 2013;28:701\u20137.","journal-title":"Korean J Intern Med"},{"key":"3387_CR51","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.jacc.2005.04.050","volume":"46","author":"N Gali\u00e8","year":"2005","unstructured":"Gali\u00e8 N, Badesch D, Oudiz R, et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2005;46:529\u201335.","journal-title":"J Am Coll Cardiol"},{"key":"3387_CR52","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1016\/j.jacc.2009.07.033","volume":"54","author":"RJ Oudiz","year":"2009","unstructured":"Oudiz RJ, Gali\u00e8 N, Olschewski H, et al. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54:1971\u201381.","journal-title":"J Am Coll Cardiol"},{"key":"3387_CR53","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.amjcard.2011.03.037","volume":"108","author":"JR Klinger","year":"2011","unstructured":"Klinger JR, Oudiz RJ, Spence R, Despain D, Dufton C. Long-term pulmonary hemodynamic effects of ambrisentan in pulmonary arterial hypertension. Am J Cardiol. 2011;108:302\u20137.","journal-title":"Am J Cardiol"},{"key":"3387_CR54","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1002\/pds.5671","volume":"32","author":"K Jeon","year":"2023","unstructured":"Jeon K, Yoo SB, Lee Y, et al. Safety and effectiveness of ambrisentan in real clinical practice in pulmonary arterial hypertension: results from the Korean post-marketing surveillance. Pharmacoepidemiol Drug Saf. 2023;32:1387\u201394.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"3387_CR55","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.healun.2016.04.013","volume":"36","author":"JL Vachi\u00e9ry","year":"2017","unstructured":"Vachi\u00e9ry JL, Hoeper MM, Peacock AJ, et al. Ambrisentan use for pulmonary arterial hypertension in a post-authorization drug registry: the VOLibris tracking study. J Heart Lung Transplant. 2017;36:399\u2013406.","journal-title":"J Heart Lung Transplant"},{"key":"3387_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jchf.2014.07.013","volume":"3","author":"RN Channick","year":"2015","unstructured":"Channick RN, Delcroix M, Ghofrani HA, et al. Effect of macitentan on hospitalizations: results from the SERAPHIN trial. JACC Heart Fail. 2015;3:1\u20138.","journal-title":"JACC Heart Fail"},{"key":"3387_CR57","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.chest.2016.08.1473","volume":"151","author":"S Mehta","year":"2017","unstructured":"Mehta S, Sastry BKS, Souza R, et al. Macitentan improves health-related quality\u00a0of life for patients with pulmonary arterial hypertension: results from the randomized controlled SERAPHIN trial. Chest. 2017;151:106\u201318 (Erratum in: Chest. 2018;153:1287).","journal-title":"Chest"},{"key":"3387_CR58","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1093\/eurheartj\/ehx025","volume":"38","author":"N Gali\u00e8","year":"2017","unstructured":"Gali\u00e8 N, Jansa P, Pulido T, et al. SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension. Eur Heart J. 2017;38:1147\u201355.","journal-title":"Eur Heart J"},{"key":"3387_CR59","doi-asserted-by":"publisher","first-page":"4374","DOI":"10.1007\/s12325-022-02199-x","volume":"39","author":"R Souza","year":"2022","unstructured":"Souza R, Delcroix M, Gali\u00e8 N, et al. Long-term safety, tolerability and survival in patients with pulmonary arterial hypertension treated with macitentan: results from the SERAPHIN open-label extension. Adv Ther. 2022;39:4374\u201390.","journal-title":"Adv Ther"},{"key":"3387_CR60","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.jcmg.2021.07.027","volume":"15","author":"A Vonk Noordegraaf","year":"2022","unstructured":"Vonk Noordegraaf A, Channick R, Cottreel E, et al. The REPAIR study: effects of macitentan on RV structure and function in pulmonary arterial hypertension. JACC Cardiovasc Imaging. 2022;15:240\u201353.","journal-title":"JACC Cardiovasc Imaging"},{"key":"3387_CR61","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s40119-023-00345-2","volume":"13","author":"A Torbicki","year":"2024","unstructured":"Torbicki A, Channick R, Gali\u00e8 N, et al. Effect of macitentan in pulmonary arterial hypertension and the relationship between echocardiography and cMRI variables: repair echocardiography sub-study results. Cardiol Ther. 2024;13:173\u201390.","journal-title":"Cardiol Ther"},{"key":"3387_CR62","doi-asserted-by":"publisher","DOI":"10.1002\/pul2.12150","volume":"12","author":"VV McLaughlin","year":"2022","unstructured":"McLaughlin VV, Channick R, Kim NH, et al. Safety of macitentan for the treatment of pulmonary hypertension: real-world experience from the OPsumit\u00ae USers Registry (OPUS) and OPsumit\u00ae Historical USers cohort (OrPHeUS). Pulm Circ. 2022;12:e12150.","journal-title":"Pulm Circ"},{"key":"3387_CR63","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1177\/0091270009341182","volume":"49","author":"E Gr\u00fcnig","year":"2009","unstructured":"Gr\u00fcnig E, Michelakis E, Vachi\u00e9ry JL, et al. Acute hemodynamic effects of single-dose sildenafil when added to established bosentan therapy in patients with pulmonary arterial hypertension: results of the COMPASS-1 study. J Clin Pharmacol. 2009;49:1343\u201352.","journal-title":"J Clin Pharmacol"},{"key":"3387_CR64","doi-asserted-by":"publisher","first-page":"204589321774148","DOI":"10.1177\/2045893217741480","volume":"8","author":"RL Benza","year":"2018","unstructured":"Benza RL, Raina A, Gupta H, et al. Bosentan-based, treat-to-target therapy in patients with pulmonary arterial hypertension: results from the COMPASS-3 study. Pulm Circ. 2018;8:2045893217741480.","journal-title":"Pulm Circ"},{"key":"3387_CR65","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.healun.2010.11.009","volume":"30","author":"RJ Barst","year":"2011","unstructured":"Barst RJ, Oudiz RJ, Beardsworth A, et al. Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension. J Heart Lung Transplant. 2011;30:632\u201343.","journal-title":"J Heart Lung Transplant"},{"key":"3387_CR66","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1183\/09031936.00116313","volume":"43","author":"O Sitbon","year":"2014","unstructured":"Sitbon O, Ja\u00efs X, Savale L, et al. Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. Eur Respir J. 2014;43:1691\u20137.","journal-title":"Eur Respir J"},{"key":"3387_CR67","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1183\/09031936.00209914","volume":"46","author":"F Dardi","year":"2015","unstructured":"Dardi F, Manes A, Palazzini M, et al. Combining bosentan and sildenafil in pulmonary arterial hypertension patients failing monotherapy: real-world insights. Eur Respir J. 2015;46:414\u201321.","journal-title":"Eur Respir J"},{"key":"3387_CR68","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.healun.2018.11.006","volume":"38","author":"JL Vachi\u00e9ry","year":"2019","unstructured":"Vachi\u00e9ry JL, Gali\u00e8 N, Barber\u00e1 JA, et al. Initial combination therapy with ambrisentan + tadalafil on pulmonary arterial hypertension-related hospitalization in the AMBITION trial. J Heart Lung Transplant. 2019;38:194\u2013202.","journal-title":"J Heart Lung Transplant"},{"key":"3387_CR69","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.rmed.2017.03.025","volume":"126","author":"S Shapiro","year":"2017","unstructured":"Shapiro S, Torres F, Feldman J, et al. Clinical and hemodynamic improvements after adding ambrisentan to background PDE5i therapy in patients with pulmonary arterial hypertension exhibiting a suboptimal therapeutic response (ATHENA-1). Respir Med. 2017;126:84\u201392.","journal-title":"Respir Med"},{"key":"3387_CR70","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.chest.2019.09.009","volume":"157","author":"M D'Alto","year":"2020","unstructured":"D\u2019Alto M, Badagliacca R, Argiento P, et al. Risk reduction and right heart reverse remodeling by upfront triple combination therapy in pulmonary arterial hypertension. Chest. 2020;157:376\u201383.","journal-title":"Chest"},{"key":"3387_CR71","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/hr.2014.28","volume":"37","author":"Y Zhuang","year":"2014","unstructured":"Zhuang Y, Jiang B, Gao H, Zhao W. Randomized study of adding tadalafil to existing ambrisentan in pulmonary arterial hypertension. Hypertens Res. 2014;37:507\u201312.","journal-title":"Hypertens Res"},{"key":"3387_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40256-017-0260-1","volume":"18","author":"P Jansa","year":"2018","unstructured":"Jansa P, Pulido T. Macitentan in pulmonary arterial hypertension: a focus on combination therapy in the SERAPHIN trial. Am J Cardiovasc Drugs. 2018;18:1\u201311.","journal-title":"Am J Cardiovasc Drugs"},{"key":"3387_CR73","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.jacc.2023.10.045","volume":"83","author":"E Gr\u00fcnig","year":"2024","unstructured":"Gr\u00fcnig E, Jansa P, Fan F, et al. Randomized trial of macitentan\/tadalafil single-tablet combination therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2024;83:473\u201384.","journal-title":"J Am Coll Cardiol"},{"key":"3387_CR74","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1016\/j.jacc.2021.07.057","volume":"78","author":"KM Chin","year":"2021","unstructured":"Chin KM, Sitbon O, Doelberg M, et al. Three- versus two-drug therapy for patients with newly diagnosed pulmonary arterial hypertension. J Am Coll Cardiol. 2021;78:1393\u2013403.","journal-title":"J Am Coll Cardiol"},{"key":"3387_CR75","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1002\/ejhf.3319","volume":"26","author":"VV McLaughlin","year":"2024","unstructured":"McLaughlin VV, Sitbon O, Chin KM, et al. Initial combination therapy with macitentan and tadalafil in patients with pulmonary arterial hypertension, with and without cardiac comorbidities. Eur J Heart Fail. 2024;26:2379\u201391.","journal-title":"Eur J Heart Fail"},{"key":"3387_CR76","doi-asserted-by":"publisher","first-page":"4205","DOI":"10.1007\/s12325-024-02964-0","volume":"41","author":"KM Chin","year":"2024","unstructured":"Chin KM, Channick R, Kim NH, et al. Macitentan and tadalafil combination therapy in incident and prevalent pulmonary arterial hypertension: real-world evidence from the OPUS\/OrPHeUS studies. Adv Ther. 2024;41:4205\u201327.","journal-title":"Adv Ther"},{"key":"3387_CR77","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s40256-020-00426-w","volume":"21","author":"HY Kuang","year":"2021","unstructured":"Kuang HY, Li Q, Du HA, Chen M, Yin YH. Efficacy and safety of long-term oral bosentan in different types of pulmonary arterial hypertension: a systematic review and meta-analysis. Am J Cardiovasc Drugs. 2021;21:181\u201391.","journal-title":"Am J Cardiovasc Drugs"},{"key":"3387_CR78","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s40261-017-0602-4","volume":"38","author":"T Takahashi","year":"2018","unstructured":"Takahashi T, Hayata S, Kobayashi A, Onaka Y, Ebihara T, Hara T. Surveillance on the safety and efficacy of ambrisentan (Volibris tablet 2.5\u00a0mg) in patients with pulmonary arterial hypertension in real clinical practice: post-marketing surveillance (interim analysis report). Clin Drug Investig. 2018;38:219\u201329.","journal-title":"Clin Drug Investig"},{"key":"3387_CR79","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jacc.2012.03.025","volume":"60","author":"O Ben-Yehuda","year":"2012","unstructured":"Ben-Yehuda O, Pizzuti D, Brown A, et al. Long-term hepatic safety of ambrisentan in patients with pulmonary arterial hypertension. J Am Coll Cardiol. 2012;60:80\u20131.","journal-title":"J Am Coll Cardiol"},{"key":"3387_CR80","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s40264-015-0275-y","volume":"38","author":"M Aversa","year":"2015","unstructured":"Aversa M, Porter S, Granton J. Comparative safety and tolerability of endothelin receptor antagonists in pulmonary arterial hypertension. Drug Saf. 2015;38:419\u201335.","journal-title":"Drug Saf"},{"key":"3387_CR81","doi-asserted-by":"publisher","first-page":"239","DOI":"10.21037\/cdt.2019.03.02","volume":"9","author":"YJ Zhang","year":"2019","unstructured":"Zhang YJ, Wang N, Gu ZC, et al. A network meta-analysis for safety of endothelin receptor antagonists in pulmonary arterial hypertension. Cardiovasc Diagn Ther. 2019;9:239\u201349.","journal-title":"Cardiovasc Diagn Ther"},{"key":"3387_CR82","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1124\/jpet.116.234930","volume":"361","author":"M Vercauteren","year":"2017","unstructured":"Vercauteren M, Trensz F, Pasquali A, et al. Endothelin ETA receptor blockade, by activating ETB receptors, increases vascular permeability and induces exaggerated fluid retention. J Pharmacol Exp Ther. 2017;361:322\u201333.","journal-title":"J Pharmacol Exp Ther"},{"key":"3387_CR83","doi-asserted-by":"publisher","first-page":"113","DOI":"10.5414\/CPP44113","volume":"44","author":"PL van Giersbergen","year":"2006","unstructured":"van Giersbergen PL, Halabi A, Dingemanse J. Pharmacokinetic interaction between bosentan and the oral contraceptives norethisterone and ethinyl estradiol. Int J Clin Pharmacol Ther. 2006;44:113\u20138.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"3387_CR84","doi-asserted-by":"publisher","first-page":"313","DOI":"10.2165\/11534940-000000000-00000","volume":"30","author":"R Spence","year":"2010","unstructured":"Spence R, Mandagere A, Walker G, Dufton C, Boinpally R. Effect of steady-state ambrisentan on the pharmacokinetics of a single dose of the oral contraceptive norethindrone (norethisterone) 1\u00a0mg\/ethinylestradiol 35 microg in healthy subjects: an open-label, single-sequence, single-centre study. Clin Drug Investig. 2010;30:313\u201324.","journal-title":"Clin Drug Investig"},{"key":"3387_CR85","doi-asserted-by":"publisher","first-page":"175346662312236","DOI":"10.1177\/17534666231223606","volume":"18","author":"S Dong","year":"2024","unstructured":"Dong S, Guo X, Wang H, Sun C. Liver injury due to endothelin receptor antagonists: a real-world study based on post-marketing drug monitoring data. Ther Adv Respir Dis. 2024;18:17534666231223606.","journal-title":"Ther Adv Respir Dis"},{"key":"3387_CR86","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1067\/mcp.2001.114667","volume":"69","author":"K Fattinger","year":"2001","unstructured":"Fattinger K, Funk C, Pantze M, et al. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther. 2001;69:223\u201331.","journal-title":"Clin Pharmacol Ther"},{"key":"3387_CR87","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1124\/jpet.114.214106","volume":"350","author":"A Treiber","year":"2014","unstructured":"Treiber A, \u00c4\u00e4nismaa P, de Kanter R, et al. Macitentan does not interfere with hepatic bile salt transport. J Pharmacol Exp Ther. 2014;350:130\u201343.","journal-title":"J Pharmacol Exp Ther"},{"key":"3387_CR88","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1124\/jpet.114.220491","volume":"352","author":"JG Kenna","year":"2015","unstructured":"Kenna JG, Stahl SH, Eakins JA, et al. Multiple compound-related adverse properties contribute to liver injury caused by endothelin receptor antagonists. J Pharmacol Exp Ther. 2015;352:281\u201390.","journal-title":"J Pharmacol Exp Ther"},{"key":"3387_CR89","doi-asserted-by":"publisher","DOI":"10.1177\/2045894018797273","volume":"8","author":"KR Patel","year":"2018","unstructured":"Patel KR, Blair CJ, Tislow JD. Hepatic safety of ambrisentan alone and in combination with tadalafil: a post-hoc analysis of the AMBITION trial. Pulm Circ. 2018;8:2045894018797273.","journal-title":"Pulm Circ"},{"key":"3387_CR90","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.19873","volume":"7","author":"WB Feldman","year":"2024","unstructured":"Feldman WB, Mahesri M, Sarpatwari A, et al. Removing the FDA\u2019s boxed hepatotoxicity warning and liver function testing requirement for ambrisentan. JAMA Netw Open. 2024;7:e2419873.","journal-title":"JAMA Netw Open"},{"key":"3387_CR91","volume":"10","author":"R Scagliola","year":"2023","unstructured":"Scagliola R, Brunelli C, Balbi M. Pulmonary arterial hypertension in the elderly: peculiar features and challenges for a proper phenotyping approach. J Cardiovasc Dev Dis. 2023;10:401.","journal-title":"J Cardiovasc Dev Dis"},{"key":"3387_CR92","doi-asserted-by":"publisher","first-page":"184","DOI":"10.5603\/CJ.a2018.0096","volume":"27","author":"N Rothbard","year":"2020","unstructured":"Rothbard N, Agrawal A, Fischer C, Talwar A, Sahni S. Pulmonary arterial hypertension in the elderly: clinical perspectives. Cardiol J. 2020;27:184\u201393.","journal-title":"Cardiol J"},{"key":"3387_CR93","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1164\/rccm.201801-0059LE","volume":"198","author":"GA Heresi","year":"2018","unstructured":"Heresi GA, Love TE, Tonelli AR, Highland KB, Dweik RA. Choice of initial oral therapy for pulmonary arterial hypertension: age and long-term survival. Am J Respir Crit Care Med. 2018;198:1090\u20133.","journal-title":"Am J Respir Crit Care Med"},{"key":"3387_CR94","doi-asserted-by":"publisher","first-page":"1702310","DOI":"10.1183\/13993003.02310-2017","volume":"51","author":"C Hjalmarsson","year":"2018","unstructured":"Hjalmarsson C, R\u00e5degran G, Kylhammar D, et al. Impact of age and comorbidity on risk stratification in idiopathic pulmonary arterial hypertension. Eur Respir J. 2018;51:1702310.","journal-title":"Eur Respir J"},{"issue":"9","key":"3387_CR95","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/j.amjcard.2012.06.040","volume":"110","author":"S Shapiro","year":"2012","unstructured":"Shapiro S, Pollock DM, Gillies H, et al. Frequency of edema in patients with pulmonary arterial hypertension receiving ambrisentan. Am J Cardiol. 2012;110(9):1373\u20137.","journal-title":"Am J Cardiol"},{"key":"3387_CR96","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhlto.2024.100197","volume":"7","author":"R Channick","year":"2025","unstructured":"Channick R, Medrek S, Delcroix M, et al. Effects of macitentan and selexipag across prognostic age groups in patients with pulmonary arterial hypertension. JHLT Open. 2025;7:100197.","journal-title":"JHLT Open"},{"key":"3387_CR97","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1161\/CIRCULATIONAHA.106.630715","volume":"114","author":"N Gali\u00e8","year":"2006","unstructured":"Gali\u00e8 N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation. 2006;114:48\u201354.","journal-title":"Circulation"},{"key":"3387_CR98","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1016\/j.amjcard.2011.07.006","volume":"108","author":"O Monfredi","year":"2011","unstructured":"Monfredi O, Griffiths L, Clarke B, Mahadevan VS. Efficacy and safety of bosentan for pulmonary arterial hypertension in adults with congenital heart disease. Am J Cardiol. 2011;108:1483\u20138.","journal-title":"Am J Cardiol"},{"key":"3387_CR99","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.cardfail.2012.02.004","volume":"18","author":"MG Kaya","year":"2012","unstructured":"Kaya MG, Lam YY, Erer B, et al. Long-term effect of bosentan therapy on cardiac function and symptomatic benefits in adult patients with Eisenmenger syndrome. J Card Fail. 2012;18:379\u201384.","journal-title":"J Card Fail"},{"key":"3387_CR100","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ijcard.2011.06.064","volume":"164","author":"JC Vis","year":"2013","unstructured":"Vis JC, Duffels MG, Mulder P, et al. Prolonged beneficial effect of bosentan treatment and 4-year survival rates in adult patients with pulmonary arterial hypertension associated with congenital heart disease. Int J Cardiol. 2013;164:64\u20139.","journal-title":"Int J Cardiol"},{"key":"3387_CR101","first-page":"638","volume":"18","author":"L Guo","year":"2014","unstructured":"Guo L, Liu YJ, Xie ZL. Safety and tolerability evaluation of oral bosentan in adult congenital heart disease associated pulmonary arterial hypertension: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci. 2014;18:638\u201345.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"3387_CR102","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000010075","volume":"97","author":"HY Kuang","year":"2018","unstructured":"Kuang HY, Wu YH, Yi QJ, et al. The efficiency of endothelin receptor antagonist bosentan for pulmonary arterial hypertension associated with congenital heart disease: a systematic review and meta-analysis. Medicine (Baltimore). 2018;97:e0075.","journal-title":"Medicine (Baltimore)"},{"key":"3387_CR103","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000015632","volume":"98","author":"Q Li","year":"2019","unstructured":"Li Q, Kuang HY, Wu YH, Lu TW, Yi QJ. What is the position of pulmonary arterial hypertension-specific drug therapy in patients with Eisenmenger syndrome: a systematic review and meta-analysis. Medicine (Baltimore). 2019;98:e15632.","journal-title":"Medicine (Baltimore)"},{"issue":"107","key":"3387_CR104","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1016\/j.amjcard.2010.12.051","volume":"1","author":"WA Zuckerman","year":"2011","unstructured":"Zuckerman WA, Leaderer D, Rowan CA, Mituniewicz JD, Rosenzweig EB. Ambrisentan for pulmonary arterial hypertension due to congenital heart disease. Am J Cardiol. 2011;1(107):1381\u20135.","journal-title":"Am J Cardiol"},{"key":"3387_CR105","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s40119-024-00361-w","volume":"13","author":"R Channick","year":"2024","unstructured":"Channick R, Chin KM, McLaughlin VV, et al. Macitentan in pulmonary arterial hypertension associated with connective tissue disease (CTD-PAH): real-world evidence from the combined OPUS\/OrPHeUS dataset. Cardiol Ther. 2024;13:315\u201339.","journal-title":"Cardiol Ther"},{"key":"3387_CR106","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1161\/CIRCULATIONAHA.118.033575","volume":"139","author":"MA Gatzoulis","year":"2019","unstructured":"Gatzoulis MA, Landzberg M, Beghetti M, et al. Evaluation of macitentan in patients with Eisenmenger syndrome. Circulation. 2019;139:51\u201363.","journal-title":"Circulation"},{"key":"3387_CR107","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1093\/eurheartj\/ehq011","volume":"31","author":"K Iversen","year":"2010","unstructured":"Iversen K, Jensen AS, Jensen TV, Vejlstrup NG, S\u00f8ndergaard L. Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial. Eur Heart J. 2010;31:1124\u201331.","journal-title":"Eur Heart J"},{"key":"3387_CR108","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.ihj.2021.07.007","volume":"73","author":"S Mohammed","year":"2021","unstructured":"Mohammed S, Vijayvergiya R, Malhotra S, Rohit MK. A randomized, double-blind, placebo-controlled study to evaluate sildenafil, ambrisentan combination therapy in pulmonary hypertension, particularly of Eisenmenger syndrome. Indian Heart J. 2021;73:633\u20136.","journal-title":"Indian Heart J"},{"key":"3387_CR109","doi-asserted-by":"publisher","first-page":"5","DOI":"10.4103\/1817-1737.58953","volume":"5","author":"S Saleemi","year":"2010","unstructured":"Saleemi S. Portopulmonary hypertension. Ann Thorac Med. 2010;5:5\u20139.","journal-title":"Ann Thorac Med"},{"key":"3387_CR110","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.healun.2019.12.008","volume":"39","author":"IR Preston","year":"2020","unstructured":"Preston IR, Burger CD, Bartolome S, et al. Ambrisentan in portopulmonary hypertension: a multicenter, open-label trial. J Heart Lung Transplant. 2020;39:464\u201372.","journal-title":"J Heart Lung Transplant"},{"key":"3387_CR111","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1183\/09031936.00117511","volume":"41","author":"L Savale","year":"2013","unstructured":"Savale L, Magnier R, Le Pavec J, et al. Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension. Eur Respir J. 2013;41:96\u2013103.","journal-title":"Eur Respir J"},{"key":"3387_CR112","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/S2213-2600(19)30091-8","volume":"7","author":"O Sitbon","year":"2019","unstructured":"Sitbon O, Bosch J, Cottreel E, et al. Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase\u00a04 trial. Lancet Respir Med. 2019;7:594\u2013604.","journal-title":"Lancet Respir Med"},{"key":"3387_CR113","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1378\/chest.10-0574","volume":"139","author":"R Cartin-Ceba","year":"2011","unstructured":"Cartin-Ceba R, Swanson K, Iyer V, Wiesner RH, Krowka MJ. Safety and efficacy of ambrisentan for the treatment of portopulmonary hypertension. Chest. 2011;139:109\u201314.","journal-title":"Chest"},{"key":"3387_CR114","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1002\/lt.25747","volume":"26","author":"M Krowka","year":"2020","unstructured":"Krowka M, Cottreel E, Hoeper MM, et al. Macitentan improves risk categorization for liver transplant mortality in patients with portopulmonary hypertension: a PORTICO study post hoc analysis. Liver Transpl. 2020;26:935\u201340.","journal-title":"Liver Transpl"},{"key":"3387_CR115","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s41030-023-00251-x","volume":"10","author":"NH Kim","year":"2024","unstructured":"Kim NH, Chin KM, McLaughlin VV, et al. Safety of macitentan for the treatment of portopulmonary hypertension: real-world evidence from the combined OPUS\/OrPHeUS studies. Pulm Ther. 2024;10:85\u2013107.","journal-title":"Pulm Ther"},{"key":"3387_CR116","doi-asserted-by":"publisher","DOI":"10.3390\/ph16091252","volume":"16","author":"A Smukowska-Gorynia","year":"2023","unstructured":"Smukowska-Gorynia A, Go\u015bciniak W, Wo\u017aniak P, et al. Recent advances in the treatment of pulmonary arterial hypertension associated with connective tissue diseases. Pharmaceuticals (Basel). 2023;16:1252.","journal-title":"Pharmaceuticals (Basel)"},{"key":"3387_CR117","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1136\/ard.2005.048967","volume":"65","author":"CP Denton","year":"2006","unstructured":"Denton CP, Humbert M, Rubin L, Black CM. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis. 2006;65:1336\u201340.","journal-title":"Ann Rheum Dis"},{"key":"3387_CR118","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1136\/ard.2007.079921","volume":"67","author":"CP Denton","year":"2008","unstructured":"Denton CP, Pope JE, Peter HH, et al. Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases. Ann Rheum Dis. 2008;67:1222\u20138.","journal-title":"Ann Rheum Dis"},{"key":"3387_CR119","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.rmed.2016.06.018","volume":"117","author":"A Fischer","year":"2016","unstructured":"Fischer A, Denton CP, Matucci-Cerinic M, et al. Ambrisentan response in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) \u2013 a subgroup analysis of the ARIES-E clinical trial. Respir Med. 2016;117:254\u201363.","journal-title":"Respir Med"},{"key":"3387_CR120","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1186\/s12872-020-01591-1","volume":"20","author":"M Li","year":"2020","unstructured":"Li M, Jing ZC, Li Y, et al. Efficacy and safety of ambrisentan in Chinese patients with connective tissue disease-pulmonary arterial hypertension: a post-hoc analysis. BMC Cardiovasc Disord. 2020;20:339.","journal-title":"BMC Cardiovasc Disord"},{"key":"3387_CR121","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1136\/annrheumdis-2019-216274","volume":"79","author":"M Kuwana","year":"2020","unstructured":"Kuwana M, Blair C, Takahashi T, Langley J, Coghlan JG. Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis. Ann Rheum Dis. 2020;79:626\u201334 (Erratum in: Ann Rheum Dis. 2020 Sep;79(9):e118).","journal-title":"Ann Rheum Dis"},{"key":"3387_CR122","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1136\/annrheumdis-2016-210236","volume":"76","author":"JG Coghlan","year":"2017","unstructured":"Coghlan JG, Gali\u00e8 N, Barber\u00e0 JA, et al. Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial. Ann Rheum Dis. 2017;76:1219\u201327.","journal-title":"Ann Rheum Dis"},{"key":"3387_CR123","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1164\/rccm.201507-1398OC","volume":"192","author":"PM Hassoun","year":"2015","unstructured":"Hassoun PM, Zamanian RT, Damico R, et al. Ambrisentan and tadalafil up-front combination therapy in scleroderma-associated pulmonary arterial hypertension. Am J Respir Crit Care Med. 2015;192:1102\u201310.","journal-title":"Am J Respir Crit Care Med"},{"key":"3387_CR124","doi-asserted-by":"publisher","DOI":"10.1177\/2045893217748307","volume":"8","author":"T Sato","year":"2018","unstructured":"Sato T, Ambale-Venkatesh B, Lima JAC, et al. The impact of ambrisentan and tadalafil upfront combination therapy on cardiac function in scleroderma associated pulmonary arterial hypertension patients: cardiac magnetic resonance feature tracking study. Pulm Circ. 2018;8:2045893217748307.","journal-title":"Pulm Circ"},{"key":"3387_CR125","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.21037\/jtd-24-151","volume":"16","author":"X Song","year":"2024","unstructured":"Song X, Sheng X, Ding L, et al. Clinical use of macitentan in the treatment of connective tissue disease-associated pulmonary arterial hypertension. J Thorac Dis. 2024;16:2060\u20139.","journal-title":"J Thorac Dis"},{"issue":"Suppl","key":"3387_CR126","doi-asserted-by":"publisher","first-page":"S508","DOI":"10.1016\/j.healun.2020.01.119","volume":"39","author":"A Ravichandran","year":"2020","unstructured":"Ravichandran A, Channick R, Chin K, et al. Treatment of drug- and toxin-induced pulmonary arterial hypertension (PAH): real-world experience with macitentan. J Heart Lung Transplant. 2020;39(Suppl):S508.","journal-title":"J Heart Lung Transplant"},{"key":"3387_CR127","first-page":"415","volume":"13","author":"R Ibrahim","year":"2006","unstructured":"Ibrahim R, Granton JT, Mehta S. An open-label, multicentre pilot study of bosentan in pulmonary arterial hypertension related to congenital heart disease. Can Respir J. 2006;13:415\u201320.","journal-title":"Can Respir J"},{"key":"3387_CR128","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.2147\/IJGM.S304992","volume":"14","author":"J Chen","year":"2021","unstructured":"Chen J, Luo J, Yang X, et al. Transition from bosentan to ambrisentan in pulmonary arterial hypertension: a single-center prospective study. Int J Gen Med. 2021;14:2101\u20137.","journal-title":"Int J Gen Med"},{"key":"3387_CR129","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1177\/1474515118769534","volume":"17","author":"A Dawson","year":"2018","unstructured":"Dawson A, Reddecliffe S, Coghlan C, Schreiber BE, Coghlan JG. Safety and feasibility audit of a home-based drug-transitioning approach for patients with pulmonary arterial hypertension: an observational study. Eur J Cardiovasc Nurs. 2018;17:612\u20138.","journal-title":"Eur J Cardiovasc Nurs"},{"key":"3387_CR130","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1378\/chest.08-1028","volume":"135","author":"MD McGoon","year":"2009","unstructured":"McGoon MD, Frost AE, Oudiz RJ, et al. Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities. Chest. 2009;135:122\u20139.","journal-title":"Chest"},{"key":"3387_CR131","doi-asserted-by":"publisher","DOI":"10.1002\/pul2.12083","volume":"12","author":"AM Aldalaan","year":"2022","unstructured":"Aldalaan AM, Saleemi SA, Weheba I, et al. Prospective clinical assessment of patients with pulmonary arterial hypertension switched from bosentan to macitentan (POTENT). Pulm Circ. 2022;12:e12083.","journal-title":"Pulm Circ"},{"key":"3387_CR132","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1017\/S1047951120000773","volume":"30","author":"E Aypar","year":"2020","unstructured":"Aypar E, Alehan D, Karag\u00f6z T, Aykan H, Ertugrul \u0130. Clinical efficacy and safety of switch from bosentan to macitentan in children and young adults with pulmonary arterial hypertension: extended study results. Cardiol Young. 2020;30:681\u20135.","journal-title":"Cardiol Young"},{"key":"3387_CR133","doi-asserted-by":"publisher","DOI":"10.1177\/2045894020945523","volume":"10","author":"NJ Verlinden","year":"2020","unstructured":"Verlinden NJ, Benza RL, Raina A. Safety and efficacy of transitioning from the combination of bosentan and sildenafil to alternative therapy in patients with pulmonary arterial hypertension. Pulm Circ. 2020;10:2045894020945523.","journal-title":"Pulm Circ"},{"key":"3387_CR134","doi-asserted-by":"publisher","first-page":"223","DOI":"10.14423\/SMJ.0000000000000607","volume":"110","author":"Z Safdar","year":"2017","unstructured":"Safdar Z, Thakur A, Frost A. Tolerability of switch to macitentan from bosentan in pulmonary arterial hypertension. South Med J. 2017;110:223\u20138.","journal-title":"South Med J"},{"key":"3387_CR135","doi-asserted-by":"publisher","first-page":"811700","DOI":"10.3389\/fphar.2021.811700","volume":"12","author":"Y Chen","year":"2022","unstructured":"Chen Y, Luo J, Chen J, et al. The transition from ambrisentan to macitentan in patients with pulmonary arterial hypertension: a real-world prospective study. Front Pharmacol. 2022;12:811700 (Erratum in: Front Pharmacol. 2022;13:891907).","journal-title":"Front Pharmacol"},{"key":"3387_CR136","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s40256-019-00392-y","volume":"20","author":"S Cadenas-Men\u00e9ndez","year":"2020","unstructured":"Cadenas-Men\u00e9ndez S, \u00c1lvarez Vega P, Oterino Manzanas A, et al. Evolution of patients with pulmonary arterial hypertension starting macitentan after the discontinuation of other endothelin-receptor antagonists: results of a retrospective study. Am J Cardiovasc Drugs. 2020;20:481\u20137.","journal-title":"Am J Cardiovasc Drugs"},{"key":"3387_CR137","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1177\/0300060519840130","volume":"47","author":"T Tynan","year":"2019","unstructured":"Tynan T, Hird K, Hannon T, Gabbay E. Pulmonary arterial hypertension outcomes upon endothelin-1 receptor antagonist switch to macitentan. J Int Med Res. 2019;47:2177\u201386.","journal-title":"J Int Med Res"},{"key":"3387_CR138","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.977110","volume":"9","author":"J Li","year":"2022","unstructured":"Li J, Yang ZY, Wang S, et al. Efficacy and safety of switching from bosentan or ambrisentan to macitentan in pulmonary arterial hypertension: a systematic review and meta-analysis. Front Cardiovasc Med. 2022;9:977110.","journal-title":"Front Cardiovasc Med"},{"key":"3387_CR139","volume":"2018","author":"SG Gong","year":"2018","unstructured":"Gong SG, Wang L, Pudasaini B, et al. Transition from ambrisentan to bosentan in pulmonary arterial hypertension: a single-center prospective study. Can Respir J. 2018;2018:9836820.","journal-title":"Can Respir J"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03387-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03387-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03387-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T19:03:17Z","timestamp":1771268597000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03387-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":139,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["3387"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03387-1","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,5]]},"assertion":[{"value":"6 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Naomi G. Habib is a consultant and has received speaker fees from Johnson & Johnson, Liquidia, Merck, Pulmovant, and United Therapeutics. Ankita Adhia, David Lopez, and Marinella Sandros are employees of Johnson & Johnson; Paul Guichard received speaker fees from Bayer, Merck, Johnson & Johnson and United Therapeutics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Ethics approval was not required\u2014this narrative review was based on previously published studies and no new studies involving human or animal participants were performed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}